References
- Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10:101–9. doi:https://doi.org/10.1038/nrd3365.
- Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–34. doi:https://doi.org/10.1093/glycob/cwv065.
- Yu X, Marshall MJE, Cragg MS. Improving Antibody-Based CM. Cancer Therapeutics Through Glycan Engineering. BioDrugs Clin Immunother Biopharm Gene Ther. 2017;31:151–66. doi:https://doi.org/10.1007/s40259-017-0223-8.
- Zhang A, Tsang VL, Markely LR, Kurt L, Huang YM, Prajapati S, Kshirsagar R. Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines. Biotechnology and Bioengineering. 2016;113:2367–76. doi:https://doi.org/10.1002/bit.25995.
- Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017;114:3485–90. doi:https://doi.org/10.1073/pnas.1702173114.
- Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. doi:https://doi.org/10.1074/jbc.M202069200.
- Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs. 2012;4(3):326–40. doi:https://doi.org/10.4161/mabs.19941.
- Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fc gamma receptor profile. J Immunol. 1950;2017(199):204–11.
- Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. Journal of Immunology (Baltimore, Md. 1950;2001:7496–503.
- Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015;171:763–75. doi:https://doi.org/10.1111/bjh.13764.
- Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu –positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:1789–96. doi:https://doi.org/10.1200/JCO.2007.14.8957.
- Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3940–47. doi:https://doi.org/10.1200/JCO.2003.05.013.
- Ackerman ME, Dugast AS, McAndrew EG, Tsoukas S, Licht AF, Irvine DJ, Alter G. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J Virol. 2013;87:5468–76. doi:https://doi.org/10.1128/JVI.03403-12.
- Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366:8–19. doi:https://doi.org/10.1016/j.jim.2010.12.016.
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–19. doi:https://doi.org/10.1038/78682.
- Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 2012;32:9677–89. doi:https://doi.org/10.1523/JNEUROSCI.4742-11.2012.
- Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537:50–56. doi:https://doi.org/10.1038/nature19323.
- Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368. doi:https://doi.org/10.3389/fimmu.2015.00368.
- Coughlin J, Masci A, Gronke RS, Bergelson S, Co C. A simple enzyme-substrate localized conjugation method to generate immobilized, functional glutathione S-transferase fusion protein columns for affinity enrichment. Anal Biochem. 2016;505:51–58. doi:https://doi.org/10.1016/j.ab.2016.03.024.
- Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics J Am Soc Exper NeuroTher. 2013;10:459–72. doi:https://doi.org/10.1007/s13311-013-0187-4.
- Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. mAbs. 2012;4:475–87. doi:https://doi.org/10.4161/mabs.20737.
- Lippold S, Nicolardi S, Dominguez-Vega E, Heidenreich AK, Vidarsson G, Reusch D, Haberger M, Wuhrer M, Falck D. Glycoform-resolved FcRIIIa affinity chromatography-mass spectrometry. mAbs. 2019;11:1191–96. doi:https://doi.org/10.1080/19420862.2019.1636602.
- Bolton GR, Ackerman ME, Boesch AW. Separation of nonfucosylated antibodies with immobilized FcgammaRIII receptors. Biotechnol Prog. 2013;29:825–28. doi:https://doi.org/10.1002/btpr.1717.
- Ulvestad E, Williams K, Matre R, Nyland H, Olivier A, Antel J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J Neuropathol Exp Neurol. 1994;53:27–36. doi:https://doi.org/10.1097/00005072-199401000-00004.
- Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc gamma receptor. mAbs. 2016;8:1512–24. doi:https://doi.org/10.1080/19420862.2016.1218586.
- Kute T, Stehle JR Jr., Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology. 2012;1:810–21. doi:https://doi.org/10.4161/onci.20447.
- Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7:2517–27. doi:https://doi.org/10.1158/1535-7163.MCT-08-0201.
- Indik ZK, Park JG, Hunter S, Schreiber AD. The molecular dissection of Fc gamma receptor mediated phagocytosis. Blood. 1995;86:4389–99. doi:https://doi.org/10.1182/blood.V86.12.4389.bloodjournal86124389.
- Downey GP, Botelho RJ, Butler JR, Moltyaner Y, Chien P, Schreiber AD, Grinstein S. Phagosomal maturation, acidification, and inhibition of bacterial growth in nonphagocytic cells transfected with FcgammaRIIA receptors. J Biol Chem. 1999;274:28436–44. doi:https://doi.org/10.1074/jbc.274.40.28436.
- Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Rüger P, Reusch D. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PloS One. 2015;10:e0134949. doi:https://doi.org/10.1371/journal.pone.0134949.
- Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law C-L, Sussman D. Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci U S A. 2013;110(14):5404–09. doi:https://doi.org/10.1073/pnas.1222263110.
- Yang WC, Lu J, Kwiatkowski C, Yuan H, Kshirsagar R, Ryll T, Huang Y-M. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol Prog. 2014;30(3):616–25. doi:https://doi.org/10.1002/btpr.1884.
- Halle M, Tribout-Jover P, Lanteigne A-M, Boulais J, St-Jean JR, Jodoin R, Girouard M-P, Constantin F, Migneault A, Renaud F. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. J Immunol Methods. 2015;424:64–79. doi:https://doi.org/10.1016/j.jim.2015.05.002.